# US 2024/0083844 A1 · Kinase inhibitors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0083844 A1
- Document ID: US20240083844A1
- Status: Published application
- Kind: A1
- Application number: 18/266,793
- Filed: 2021-12-16
- Published: 2024-03-14
- Earliest claimed: 2020-12-16
- Assignees: ABM Therapeutics Corporation
- Applicants: ABM Therapeutics Corporation
- Inventors: Chen CHEN
- Web page: https://patentgrep.com/patent/US20240083844A1

## CPC

- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- A61K 31/4427: containing further heterocyclic ring systems
- A61K 31/4462: only substituted in position 3
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C07D 207/14: Nitrogen atoms not forming part of a nitro radical
- C07D 211/56: Nitrogen atoms (nitro radicals C07D211/38)
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are kinases inhibitors, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, such as methods of treating a proliferation disorder, such as a cancer or a tumor, or in some embodiments disease or disorders related to the dysregulation of kinase such as, but not limited to kinases such as MEK, COT1, FGFR4, MINK, MYO3A, PKG1B, and PLK3.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein:
G1 is CH or CR2
G2, G3, and G4 are independently of each other N, CH, or CR2;
provided that at least two of G2, G3, and G4 are independently of each other CH or CR2;
and further provided that when G1 is CH, then at least one of G2, G3, and G4 is N or CR2;
m is 0, 1, 2, 3, 4, or 5;
p is 0, 1, 2, 3, or 4;
q is 1, 2, or 3;
each R1 is independently selected from the group consisting of halogen, OH, NH2, NO2, CN, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —O-[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —NH(optionally substituted C1-C6 alkyl), —N(optionally substituted C1-C6 alkyl)2, —NH[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —N[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)]2, —C(═O)-(optionally substituted C1-C6 alkyl), —C(═O)-(optionally substituted C2-C6 alkenyl), and —C(═O)-(optionally substituted C2-C6 alkynyl);
each R2 is independently selected from the group consisting of halogen, OH, NH2, NO2, CN, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 alkoxy, -[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —O-[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —NH(optionally substituted C1-C6 alkyl), —N(optionally substituted C1-C6 alkyl)2, —NH[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —N[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)]2, —C(═O)-(optionally substituted C1-C6 alkyl), —C(═O)-(optionally substituted C2-C6 alkenyl), and —C(═O)-(optionally substituted C2-C6 alkynyl);
each R3 is independently selected from the group consisting of halogen, OH, NH2, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, -[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], optionally substituted C1-C6 alkylene-COOH, optionally substituted C1-C6 alkylene-C(═O)—O-(optionally substituted C1-C6 alkyl), optionally substituted C1-C6 alkoxy, —O-[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —NH(optionally substituted C1-C6 alkyl), —N(optionally substituted C1-C6 alkyl)2, —NH[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —N[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)]2, —C(═O)-(optionally substituted C1-C6 alkyl), —C(═O)-(optionally substituted C2-C6 alkenyl), and —C(═O)-(optionally substituted C2-C6 alkynyl); and
R4 is selected from the group consisting of hydrogen, halogen, OH, NH2, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, -[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], optionally substituted C1-C6 alkylene-COOH, optionally substituted C1-C6 alkylene-C(═O)—O-(optionally substituted C1-C6 alkyl), optionally substituted C1-C6 alkoxy, —O-[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —NH(optionally substituted C1-C6 alkyl), —N(optionally substituted C1-C6 alkyl)2, —NH[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —N[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)]2, —C(═O)-(optionally substituted C1-C6 alkyl), —C(═O)-(optionally substituted C2-C6 alkenyl), and —C(═O)-(optionally substituted C2-C6 alkynyl).

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein the compound of Formula (I) is a compound of Formula (I-1):
or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G1, G2, G3, G4, p, q, R1, R2, R3, and R4 are as defined for Formula (I).

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein the compound of Formula (I) is a compound of Formula (I-2a), (I-2b), or (I-2c):
or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G1, G2, G3, G4, p, R1, R2, R3, and R4 are as defined for Formula (I).

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein the compound of Formula (I) is a compound of Formula (I-3a), (I-3b), or (I-3c):
or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G1, G2, G3, G4, R1, R2, R3, and R4 are as defined for Formula (I).

### Claim 5 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G1 is CH.

### Claim 6 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G1 is CR2.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G2 is N.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G2 is CH.

### Claim 9 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G2 is CR2.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G3 is N.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G3 is CH.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G3 is CR2.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G4 is N.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G4 is CH.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G4 is CR2.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The compound of any one of claims 1-14, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G4 is CR2.

### Claim 17 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G1 is CH, G2 is CF, G3 is CH, and G4 is CF.

### Claim 18 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein wherein G1 is CF, G2 is CF, G3 is CF, and G4 is CF.

### Claim 19 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G1 is CH, G2 is N, G3 is CH, and G4 is CH.

### Claim 20 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G1 is CH, G2 is N, G3 is CH, and G4 is CF.

### Claim 21 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G1 is CH, G2 is N, G3 is CH, and G4 is CCl.

### Claim 22 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein G1 is CH, G2 is CH, G3 is N, and G4 is CH.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The compound of any one of claims 1-22, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein each R1 is independently selected from the group consisting of halogen and optionally substituted C2-C6 alkynyl.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The compound of any one of claims 1-22, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein m is 2 and each R1 is independently selected from the group consisting of halogen and optionally substituted C2-C6 alkynyl.

### Claim 25 (depends on 24)

The compound of claim 24, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein one R1 is halogen and the other R1 is optionally substituted C2-C6 alkynyl.

### Claim 26 (depends on 25)

The compound of claim 25, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein one R1 is fluoro and the other R1 is ethynyl.

### Claim 27 (depends on 24)

The compound of claim 24, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein each R1 is indepdently selected from the group consisting of fluoro, chloro, bromo, and iodo.

### Claim 28 (depends on 27)

The compound of claim 27, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein one R1 is fluoro and the other R1 is iodo.

### Claim 29 (depends on 27)

The compound of claim 27, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein one R1 is chloro and the other R1 is bromo.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound of any one of claims 1-29, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein R4 is hydrogen.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound of any one of claims 1-29, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein R4 is selected from the group consisting of optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, and -[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)].

### Claim 32 (depends on 31)

The compound of claim 31, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein R4 is optionally substituted C1-C6 alkyl.

### Claim 33 (depends on 32)

The compound of claim 32, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein R4 is selected from the group consisting of methyl, ethyl, and prop-2-yl.

### Claim 34 (depends on 31)

The compound of claim 31, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein R4 is optionally substituted C1-C6 haloalkyl.

### Claim 35 (depends on 34)

The compound of claim 34, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein R4 is 2-fluoroeth-1-yl.

### Claim 36 (depends on 31)

The compound of claim 31, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein R4 is -[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)].

### Claim 37 (depends on 36)

The compound of claim 36, or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein R4 is 2-methoxyeth-1-yl.

### Claim 38

A compound selected from a compound of Table 1:
Compound
No.
Structure
Chemical Name
1
N-(azetidin-3-yl)-2,4- difluoro-6-((2-fluoro-4- iodophenyl)amino)benzamide
2
2,4-difluoro-6-((2-fluoro-4- iodophenyl)amino)-N- (pyrrolidin-3-yl)benzamide
3
2,4-difluoro-6-((2-fluoro-4- iodophenyl)amino)-N- (piperidin-3-yl)benzamide
4
N-(azetidin-3-y1)-2,3,4,5- tetrafluoro-6-((2-fluoro-4- iodophenyl)amino)benzamide
5
N-(azetidin-3-y1)-3-fluoro-5- ((2-fluoro-4-iodophenyl) amino)isonicotinamide
6
N-(1-ethylazetidin-3-y1)-3- fluoro-5-((2-fluoro-4- iodophenyl)amino) isonicotinamide
7
3-fluoro-5-((2-fluoro-4- iodophenyl)amino)-N-(1- methylazetidin-3- yl)isonicotinamide
8
3-fluoro-5-((2-fluoro-4- iodophenyl)amino)-N-(1- isopropylazetidin-3- yl)isonicotinamide
9
3-fluoro-5-((2-fluoro-4- iodophenyl)amino)-N-(1-(2- fluoroethyl)azetidin-3- yl)isonicotinamide
10
3-fluoro-5-((2-fluoro-4- iodophenyl)amino)-N-(1-(2- methoxyethyl)azetidin-3- yl)isonicotinamide
11
N-(azetidin-3-y1)-3-((4- ethyny1-2- fluorophenyl)amino)-5- fluoroisonicotinamide
12
N-(1-ethylazetidin-3-y1)-3- ((4-ethynyl-2- fluorophenyl)amino)-5- fluoroisonicotinamide
13
N-(azetidin-3-y1)-3-chloro-5- ((2-fluoro-4-iodophenyl) amino)isonicotinamide
14
N-(azetidin-3-yl)-3-((4- bromo-2- chlorophenyl)amino)-5- fluoroisonicotinamide
15
N-(azetidin-3-yl)-3-((2- fluoro-4- iodophenyl)amino) isonicotinamide
16
N-(azetidin-3-yl)-4-((2- fluoro-4- iodophenyl)amino) nicotinamide
17
3-((4-acetyl-2- fluorophenyl)amino)-N- (azetidin-3-y1)-5- fluoroisonicotinamide
18
3-(3-(3-((2-fluoro-4- iodophenyl)amino)isonicotina mido)azetidin-1-yl)propanoic acid
19
4-(3-(3-((2-fluoro-4- iodophenyl)amino)isonicotina mido)azetidin-1-yl)butanoic acid
20
N-(1-acetylazetidin-3-y1)-3- fluoro-5-((2-fluoro-4- iodophenyl)amino) isonicotinamide
or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A pharmaceutical composition comprising a compound of any one of claims 1-38, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A combination comprising a compound of any of claims 1-38, or a pharmaceutically acceptable salt thereof, and a second prophylactic or therapeutic agent.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A compound according to any one of claims 1-38 for use in treating and/or preventing a proliferation disorder, such as a cancer, or a tumor in a subject.

### Claim 42 (depends on 41)

The compound of claim 41, wherein the proliferation disorder or cancer is selected from the group consisting of malignant or benign tumors of the liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas, sarcomas, glioblastomas, head and neck, melanoma, and other hyperplastic conditions such as benign hyperplasia of the skin and benign hyperplasia of the prostate.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method for treating and/or preventing a proliferation disorder, such as a cancer, or a tumor in a subject, wherein the method comprises administering to the subject an effective amount of a compound of any one of claims 1-38, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition of claim 39, or a combination of claim 40.

### Claim 44 (depends on 43)

The method of claim 43, wherein the proliferation disorder or cancer is selected from the group consisting of malignant or benign tumors of the liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas, sarcomas, glioblastomas, head and neck, melanoma, and other hyperplastic conditions such as benign hyperplasia of the skin and benign hyperplasia of the prostate.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

Use of a compound according to any of claims 1-38 for the manufacture of a medicament.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method for inhibiting an activity of one or more kinases selected from the group consisting of MEK, COT1, FGFR4, MINK, MYO3A, PKG1B, and PLK3, comprising contacting the cell with an effective amount of a compound of any one of claims 1-38, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition of claim 39, or a combination of claim 40, wherein the contacting is in vitro, ex vivo, or in vivo.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A compound according to any one of claims 1-38 for use in the treatment of a neurodegenerative disease.

### Claim 48 (depends on 47)

The compound of claim 47, wherein the neurodegenerative disease is selected from the group consisting of Amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, and Huntington's disease.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method for treating a neurodegenerative disease in a subject, wherein the method comprises administering to the subject an effective amount of a compound of any one of claims 1-38, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition of claim 39, or a combination of claim 40.

### Claim 50 (depends on 49)

The method of claim 49, wherein the neurodegenerative disease is selected from the group consist of Amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, and Huntington's disease.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method for treating an immunodeficient disease in a subject, wherein the method comprises administering to the subject an effective amount of a compound of any one of claims 1-38, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition of claim 39, or a combination of claim 40.

### Claim 52 (depends on 51)

The method of claim 51, wherein the neurodegenerative disease is selected from the group consist of immunodeficient disease is selected from the group consist of cancers, infectious disease, and some genetic diseases.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method for inhibiting an activity of one or more kinases selected from the group consisting of MEK, COT1, FGFR4, MINK, MYO3A, PKG1B, and PLK3, comprising contacting the cell with an effective amount of a compound of any one of claims 1-38, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition of claim 39, or a combination of claim 40, wherein the contacting is in vitro, ex vivo, or in vivo.
